145 related articles for article (PubMed ID: 38704439)
1. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis.
Lowell JA; Sharma G; Swaminath A; Sultan K
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38704439
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
3. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.
Zhang J; Li W; Gong M; Gu Y; Zhang H; Dong B; Guo Q; Pang X; Xiang Q; He X; Cui Y
Front Pharmacol; 2023; 14():1189389. PubMed ID: 37351513
[No Abstract] [Full Text] [Related]
5. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
Gouverneur A; Avouac J; Prati C; Cracowski JL; Schaeverbeke T; Pariente A; Truchetet ME
Eur J Clin Pharmacol; 2022 Dec; 78(12):1981-1990. PubMed ID: 36284012
[TBL] [Abstract][Full Text] [Related]
7. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.
Corrao S
Intern Emerg Med; 2023 Nov; 18(8):2157-2161. PubMed ID: 37898967
[TBL] [Abstract][Full Text] [Related]
8. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
9. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation.
Con D; Hilley P; Chin S; Corte C; Hafeez B; Testro A; De Cruz P; Choy M; Srinivasan A
J Crohns Colitis; 2024 Mar; ():. PubMed ID: 38502366
[TBL] [Abstract][Full Text] [Related]
11. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings.
Philippoteaux C; Deprez V; Nottez A; Cailliau E; Houvenagel E; Deprez X; Philippe P; Pascart T; Flipo RM; Goëb V; Letarouilly JG
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615007
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
Boyce EG; Rogan EL; C Lui M
Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
[TBL] [Abstract][Full Text] [Related]
14. Clinical Issues-January 2023.
Jones E
AORN J; 2023 Jan; 117(1):70-75. PubMed ID: 36573746
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Desai RJ; Pawar A; Weinblatt ME; Kim SC
Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
[TBL] [Abstract][Full Text] [Related]
16. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
17. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
Agarwal A; Diaz A; Al-Dehneem R; Pineda RM; Khattri S
J Drugs Dermatol; 2023 Dec; 22(12):1183-1190. PubMed ID: 38051858
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
19. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
